Laboratorios Recalcine S.A. was founded in 2004. The Company's line of business included the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or veterinary use. It was a Chilean pharmaceutical company engaged in the development, production, and sale of pharmaceutical drugs in 15 Latin American countries such as Argentina, Bolivia, Chile, Colombia, Costa Rica, Ecuador, Paraguay, Peru, Venezuela, and others and Vietnam in Asia. The Company was one of the largest pharmaceutical companies in Latin America. Laboratorios Recalcine S.A. changed to CFR Pharmaceutical S.A. in 2010. In 2014, Abbott acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the Company's presence in fast-growing markets.